You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華億金控(08123.HK)旗下基金將與上海藥明康德合作開發三種新藥物
格隆匯 10-15 20:04

格隆匯10月15日丨華億金控(08123.HK)公佈,本公司直接全資附屬公司深圳華億生物科技(作為有限合夥人)已與普通合夥人訂立有限合夥協議以成立有限合夥企業。本集團於2019年9月28日獲執行合夥人知會,成都嘉葆藥銀(有限合夥企業擁有90%股份的投資實體)與上海藥明康德新藥開發有限公司訂立聯合開發協議,以合作聯合開發三種新藥物。

聯合開發協議訂明,上海藥明康德與成都嘉葆藥銀將合作聯合開發以下三種新藥物的開發項目,即(1)治療淋巴瘤的新藥物;(2)治療細胞瘤的新藥物;及(3)治療結直腸癌的新藥物。

上海藥明康德及成都嘉葆藥銀協定該等項目將採納聯合研發、風險分擔及收益分佔的模型。根據該模型,上海藥明康德及成都嘉葆藥銀將合作就該等項目項下的三種新藥物制定開發計劃,並將就研發該等項目共同申請政府的支持、補貼及獎勵以及其他優惠政策。上海藥明康德及成都嘉葆藥銀亦將合作制定商業化計劃,包括出售或取得該等項目項下三種新藥物的許可,並共同於醫學期刊或出版物刊發該等項目的研究結果及發現。成都嘉葆藥銀將擁有該等項目之知識產權及申請材料,而上海藥明康德有權根據聯合開發協議中協定的比例,分佔該等項目研發成果所產生的收入。

有限合夥人認為,透過與上海藥明康德訂立聯合開發協議,其將為有限合夥企業帶來與其中一間全球領先藥物研發服務集團合作的機會,共同參與新藥物開發項目,以尋求人類腫瘤的科學解決方案,促進人類健康與生活的改善,其將為有限合夥企業未來於新抗腫瘤藥物開發項目的領域中奠定基礎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account